was trying to make.
DR. KIBBE: Ajaz has a few comments.
DR. HUSSAIN: No. I think just in closing, this was sort of a general discussion on endogenous drugs, and I think Dale provided sort of a framework for moving forward with decision tree criteria.
The question I think I have in my mind is, as we move forward to this, does the committee feel that a decision tree criteria would be a valuable step in terms of dealing with these compounds because we will have a number of endogenous substances to deal with? The list that Dale provided, this partial list, I think the numbers are quite high, and I think we'll have to deal with every one on a case-by-case basis. But is there a framework of a decision tree that could evolve from this discussion?
DR. KIBBE: Pat?
DR. DeLUCA: Yes. I have a question just to go back on that, and I noticed when Dale was talking, he seemed to be talking about bioavailability and bioequivalence, and are we mixing things here? It seems like with the endogenous substances, bioequivalence may be something difficult to determine. The patient is the